“It appears that someone wants the dots to be connected and take their foot off the neck of AVXL. Probably the same people who have put it there in the first place”
Nice observation, K123!
Also, agree wholeheartedly that the share price should increase with every new positive aspect of our drug we continue to uncover, as well as solidifying our IP into new indications, gaining new insights to enrich our trials (the KEM and Illumina work for correlations), and overall company “completeness” - we have 2 trials approved, have solid financing available, don’t forget grants and Aus government, the outstanding credentials of our SAB along with those who share in our endeavor and support our strategic leap into precision medicine: Ariana, Federico Goodsaid - appearing at CTAD, Hampel, our preclinical results...
each of these announcements should have incrementally indicated the promise of our company/drug and our share price should have crept up.
Instead, it appears every bit of news, which the market usually associates with growth potential, has been met with bleeding down of our price.
So, something is not right. Disruption in this field is not greeted warmly but science can win out in the end.
That’s why I think the price won’t inch up, we will have to work very hard to nail down every single thing we have - sometimes requiring multiple nails, but, after we patiently perform these tasks, we should not inch up but rather jump at some point with irrefutable, conclusive evidence. When that happens, we change the field of CNS and see our reward.
Don’t look for anyone to give us any breaks until then...unless, their finger is in the pie.
Take it easy, K,
Bio
Market Data 
Markets 
AI
